320
Participants
Start Date
August 3, 2022
Primary Completion Date
March 19, 2025
Study Completion Date
June 30, 2026
BA3071
Conditionally active biologic (CAB) antibody that binds to CTLA-4
Nivolumab
Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
Pembrolizumab
Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
Pemetrexed (Alimta)
pemetrexed with either cisplatin or carboplatin
Cancer Care Foundation, Miranda
Border Medical Oncology Research Unit at Albury Wodonga Regional Cancer Centre, Albury
Cancer Research South Australia, Adelaide
Icahn School of Medicine at Mt. Sinai, New York
Piedmont West, Atlanta
University Hospitals Cleveland Medical Center, Cleveland
Northwest Cancer Centers, Dyer
University of Utah Huntsman Cancer Institute, Salt Lake City
The Angeles Clinic and Research Institute, Los Angeles
USC Norris Comprehensive Cancer Center, Los Angeles
Providence Cancer Institute, Portland
Morristown Medical Center/Atlantic Health System, Morristown
Lead Sponsor
BioAtla, Inc.
INDUSTRY